TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01229371

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inflexal V influenza vaccine (CSL HA Antigen) 2010
Description: Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using CSL HA Antigen) 2010/2011, with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inflexal V influenza vaccine (CSL HA Antigen) 2010
Description: Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using CSL HA Antigen) 2010/2011, with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inflexal V influenza vaccine (AdImmune HA antigen) 2010/2011
Description: Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA antigen) 2010/2011 with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inflexal V influenza vaccine (AdImmune HA antigen) 2010/2011
Description: Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA antigen) 2010/2011 with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
Study: NCT03225742

Intervention type: DIAGNOSTIC_TEST
Intervention: to measure the residual volume after catheterization
Description: after first micturition to measure the residual volume in bladder
Study: NCT01015417

Intervention type: OTHER
Group type: OTHER
Intervention: No medication
Description: no postoperative antibiotics
Study: NCT00826345

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture / Moxibustion
Description: Acupuncture/Moxibustion points will be administered per point prescription.~- Active

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acupuncture/Moxibustion
Description: Sham/Placebo Acupuncture/Moxibustion - Not active
Study: NCT00568711

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline
Description: a 5-day course of 100 mg bid doses of doxycycline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rifampin
Description: a 5-day course of daily 600-mg doses of rifampin
Study: NCT06163417

Intervention type: PROCEDURE
Intervention: laparoscopic
Description: laparoscopic
Study: NCT02715232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: 100mg testosterone undecanoat every 8-12 weeks, or alternatively 50mg testosterone transdermally, or 50mg testosterone creme

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lynestrenol
Description: 2-3 tablets/day, if menstruation still occurs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyproterone Acetate
Description: 25mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: 75 microgram transdermal therapeutic system twice a week, or p.o. estradiol 2x2mg/day, or estradiol gel 1,5-3mg
Study: NCT04584008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGFR Inhibitor, IDH1 Inhibitor, HER2 Inhibitor, PARP Inhibitor, BRAF Inhibitor, MEK Inhibitor, ICIs, EGFR-TKIs, NTRK-TKI, and et. al.
Description: According to the treatment dose approved by NMPA/FDA, evaluation will be conducted every 2 cycles until tumor progression or adverse events cannot be tolerated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Other Therapy
Description: Patients will receive other treatments, including cytotoxic drugs, antiangiogenic drugs, best supportive care, clinical trials of unmatched new drugs, etc..
Study: NCT00432965

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Moist Wound Therapy
Description: Moist Wound Therapy (Standard of Care)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VAC Therapy
Description: VAC Therapy
Study: NCT03478488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN035 plus Gemcitabine & oxaliplatin
Description: KN035 a programmed death ligand immune check inhibitor Per Investigator decision

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine & oxaliplatin
Description: The standard of care for the patients with unresectable/metastatic biliary tract cancer
Study: NCT03357822

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil fumarate
Description: 300mg tenofovir is orally taken every day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: 300mg tenofovir is orally taken every day
Study: NCT01996345

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical Pessary Placement
Description: For the patients assigned to receive a cervical pessary, they will be evaluated and fitted for a pessary by the physician within 3-4 days unless exclusion criteria develop. After it is placed she will be evaluated for comfort. She will be asked to leave it in at all times but informed that removal and withdrawal from the study is always her option.
Study: NCT03493308

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education
Description: PNE will be conducted in line with international guidelines and will cover the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience.
Study: NCT02715232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin acetate
Description: 4,12mg every 4-6 weeks (powder for suspension for injection s.c. or i.m.
Study: NCT03493308

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise will be provided in different formats including general exercise, strengthening, dance.
Study: NCT00540449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC278
Description: 25 mg tablet once daily for 96 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: 600mg once daily for 96 weeks
Study: NCT03524677

Intervention type: DIAGNOSTIC_TEST
Intervention: Liquid Biopsy
Description: K-RAS, CDKN2A, SMAD4 and TP53 mutation on circulating cfDNA
Study: NCT04000672

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D printed patient specific metal jigs (PSI jig)
Description: PSI jig is created based on the pre-operative CT image. Standard medial open wedge osteotomy described previously is performed. Incision is made in the midway between posteromedial border of the tibia and medial aspect of the tibial tuberosity. Sartorius fascia is cut and retracted medially to expose the medial collateral ligament (MCL). Then the PSI jig is positioned onto the tibia. Due to the jig patient specific design (individually based on each patient's CT image), it can fit closely to the proximal tibia. The slot opening on the PSI jig corresponds to 4 cm below the medial joint line and the slot design allow the sawblade cut direction toward the safe zone of the lateral cortex under fluoroscopy. The PSI Jig is removed after the bone cut completed and would not retain in patient's body.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HTO with navigation
Description: In brief, an incision is made in the midway between posteromedial border of the tibia and medial aspect of the tibial tuberosity. Sartorius fascia is cut and retracted medially to expose the medial collateral ligament (MCL). Two to three K-wires are placed 4 cm below the medial joint line toward the safe zone (an area between the tip of the fibular head and the remnant of fibular head epiphysis line) of the lateral cortex under fluoroscopy and osteotomy is done below and parallel to the k-wires using an oscillating saw leaving the lateral 10 mm intact.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HTO with navigation
Description: In brief, an incision is made in the midway between posteromedial border of the tibia and medial aspect of the tibial tuberosity. Sartorius fascia is cut and retracted medially to expose the medial collateral ligament (MCL). Two to three K-wires are placed 4 cm below the medial joint line toward the safe zone (an area between the tip of the fibular head and the remnant of fibular head epiphysis line) of the lateral cortex under fluoroscopy and osteotomy is done below and parallel to the k-wires using an oscillating saw leaving the lateral 10 mm intact.
Study: NCT04056663

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health-Circuit mobile application
Description: Health-Circuit as a collaborative tool between professionals and patient and professionals
Study: NCT00819767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren was supplied in 150 mg tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Valsartan was supplied in 160 mg capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to aliskiren
Description: Placebo to aliskiren was supplied in tablets matching aliskiren 150 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to aliskiren
Description: Placebo to aliskiren was supplied in tablets matching aliskiren 150 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to valsartan
Description: Placebo to valsartan was supplied in capsules matching valsartan 160 mg.
Study: NCT04205903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Given PO
Study: NCT00819767

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to valsartan
Description: Placebo to valsartan was supplied in capsules matching valsartan 160 mg.
Study: NCT00942812

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diarrhea Pack
Description: Low osmolality ORS, Zinc tablets, water purification tablets and pictorial chart

Intervention type: OTHER
Group type: OTHER
Intervention: ORS
Description: ORS has been supplied to diarrheal cases as standard care through the LHW program at community level
Study: NCT00776568

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extra-corporeal shockwave
Description: Low intensity shock waves are applied as 300 shocks per visit for 09 visits. The treatment visit is carried at week 1, 5 and 9.
Study: NCT04205903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib Hydrochloride Monohydrate
Description: Given PO on cycle 1 Days 7, 14, 15 once a day 24 hours prior to the paclitaxel infusion and again 30 minutes prior to the paclitaxel infusion on days 8, 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV weekly on days 1, 8, 15, of every 21 days, at a starting dose of 80mg/m2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Given IV weekly on days 1, 8, 15, of every 21 days, at a starting dose of 80mg/m2

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00453505

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: \<=1 Hz TMS for up to 30mins and up to 115% of resting motor threshold intensity (MT).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TMS
Description: \<=1 Hz TMS for up to 30mins and up to 115% of resting motor threshold intensity (MT).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS up to 2 mA for up to 60mins.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: tDCS up to 2 mA for up to 60mins.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS
Description: tACS up to 1 mA for up to 10 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tACS
Description: tACS up to 1 mA for up to 10 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPNS
Description: CPNS alone with intensities below 130% of the peripherally-elicited-motor-threshold for up to 2 hours.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CPNS
Description: CPNS alone with intensities below 130% of the peripherally-elicited-motor-threshold for up to 2 hours.
Study: NCT01562158

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard therapy
Description: Standard treatment of bleeding

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard therapy
Description: Standard treatment of bleeding

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard therapy
Description: Standard treatment of bleeding

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: standard therapy
Description: Standard treatment of bleeding

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII
Description: Two days repeated treatment regimen - low dose administered i.v. (into the vein)
Study: NCT01609959

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azilsartan
Description: Azilsartan 20 mg or 40 mg (if blood pressure does not reach the target after 6 weeks) per day for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Valsartan 160 mg per day
Study: NCT01038284

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient education
Description: Pharmaceutical care of patients with PAH
Study: NCT01562158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII
Description: Two days repeated treatment regimen - medium dose administered i.v. (into the vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII
Description: Two days repeated treatment regimen - high dose administered i.v. (into the vein)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo
Study: NCT04166500

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysteroscopy
Description: outpatient hysteroscopy after the first menstrual cycle in the follicular phase (9-12 days).
Study: NCT00920933

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisolone
Study: NCT00776568

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-hypertensive drugs
Description: ACE inhibitors, Ca channel blockers, Beta blockers, Diuretics, Cholesterol lowering agents and/or other drugs used alone or in combination, as prescribed.
Study: NCT01554085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-002158
Description: ALS-002158

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT01585870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Sorafenib (starting dose of 200 mg bid, level 1) administration will begin on Day 11 of Cycle 1, and will be administered twice daily continuously. If the combination is well tolerated, the dose will be escalated in new cohorts to 200 mg AM and 400 mg PM (level 2), then subsequently to 400 mg bid (level 3).~If sorafenib starting dose (level 1) is not well tolerated with eribulin, the sorafenib dose will be de-escalated to 200 mg qd (Dose Level -1) in a new cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Eribulin: 1.4 mg/m2 as an intravenous infusion on Days 1 and 8 of each 21-day cycle.
Study: NCT06434428

Intervention type: DRUG
Intervention: dexmedetomidine (IV)
Description: Administration of IV dexmedetomidine

Intervention type: DRUG
Intervention: dexmedetomidine (IN)
Description: Administration of IN dexmedetomidine
Study: NCT01019577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Lyophilized and solvent, IV, 10-50 mg/m2, Q3W, Maximum 9 cycles
Study: NCT01049139

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1-sided messages
Description: Supplemental information with 1-sided messages (emphasizes information content related to vaccine trial randomization and unproven efficacy of vaccine).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2-sided messages
Description: Supplemental information with 2-sided messages (acknowledges the beliefs that are at odds with the information content and seeks to neutralize those beliefs through counter-argument).
Study: NCT02664376

Intervention type: OTHER
Intervention: Sarcopenia detection
Description: The assessment of sarcopenia is performed according to the recommendations of the EWGSOP (European Working Group on Sarcopenia in Older people). Three measurements are made:~* Muscle mass measurement by dual energy X-ray absorptiometry (DEXA).~* Walking speed measurement~* Hand grip test~A diagnosis of sarcopenia is established if the walking speed is inferior to 0.8 m/sec, the muscular strength is low and the muscular mass is low.~Data regarding the geriatric characteristics of this sarcopenic population will be collected.
Study: NCT04692948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chimeric antigen receptor T cells (car-t)
Description: Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner, which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells.
Study: NCT02939001

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iris recognition scanner
Study: NCT00817050

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone Furoate Nasal Spray
Description: One dose (2 sprays in each nostril) of Mometasone Furoate Nasal Spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone Furoate Nasal Spray
Description: One dose (2 sprays in each nostril) of Mometasone Furoate Nasal Spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone nasal spray
Description: One dose (2 sprays in each nostril) of fluticasone nasal spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone nasal spray
Description: One dose (2 sprays in each nostril) of fluticasone nasal spray
Study: NCT01772719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin and zoledronic acid
Description: 1. Simvastatin 80 mg PO daily starting two days before starting chemotherapy and stopping two days after chemotherapy.~2. Zoledronic acid 4 mg IV over 15 minutes on day 1 and then monthly.
Study: NCT04549051

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tenex
Description: Local anesthetic plus Tenex into the coracohumeral ligament for adhesive capsulitis

Intervention type: DRUG
Group type: OTHER
Intervention: Local anesthetic
Description: Only local anesthetic into the coracohumeral ligament for adhesive capsulitis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local anesthetic
Description: Only local anesthetic into the coracohumeral ligament for adhesive capsulitis
Study: NCT04215913

Intervention type: OTHER
Intervention: The investigators will extract total protein, DNA and RNA from PSC patients.
Description: The investigators will extract total protein, DNA and RNA from PSC patients.
Study: NCT01038284

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Data collection
Description: Clinical and biological data, treatment, medication errors and ADEs
Study: NCT02797106

Intervention type: OTHER
Intervention: Practice survey of health professionals
Description: Survey of the practices and opinions of health care professionals to describe care pathways, assessment and treatment of drooling in children with cerebral palsy
Study: NCT00705224

Intervention type: BIOLOGICAL
Intervention: Pegylated Interferon
Description: Routine treatment with a combination of any pegylated interferon and ribavirin was used according to the label/local practice in Russia.~The treatment course duration complied with the labeled dosage regimen. Each dose of pegylated interferon was administered as a subcutaneous~injection calculated as 1.5 mcg/kg once a week. Therapy duration varied from 24 to 48 weeks depending on Hepatitis C virus (HCV) genotype, viral load, activity and stage of hepatitis C.~The Sponsor did not provide formal drug supply.

Intervention type: DRUG
Intervention: Ribavirin
Description: Routine treatment with a combination of any pegylated interferon and ribavirin was used according to the label/local practice in Russia.~The treatment course duration complied with the labeled dosage regimen. Ribavirin was taken orally as 200 mg gelatinous capsules. The daily dose varied from 800 to 1200 mg (depending on patient's body weight) twice daily in the~morning and in the evening with meal. Therapy duration varied from 24 to 48 weeks depending on HCV genotype, viral load, activity and stage of hepatitis C.~The Sponsor did not provide formal drug supply.
Study: NCT04215913

Intervention type: OTHER
Intervention: The investigators will extract total protein, DNA and RNA from PSC patients.
Description: The investigators will extract total protein, DNA and RNA from PSC patients.

Intervention type: OTHER
Intervention: The investigators will extract total protein, DNA and RNA from PSC patients.
Description: The investigators will extract total protein, DNA and RNA from PSC patients.
Study: NCT03809351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18]AV-1451-PET
Description: All study participants will undergo brain imaging with \[F-18\]AV-1451-PET/MRI. \[F-18\]AV-1451 is a PET imaging agent used primarily to measure the amount of abnormal tau protein deposition the brain.
Study: NCT01814358

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein powder
Description: Subjects on this arm will consume 20g whey protein powder mixed with water 15 minutes prior to breakfast, lunch, and dinner for two days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control protein
Description: Subjects on this arm will consume 20g gelatin protein powder mixed with water 15 minutes prior to breakfast, lunch, and dinner for two days